Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-1-16
pubmed:abstractText
A major question regarding the sensitivity of solid tumors to targeted kinase inhibitors is why some tumors respond and others do not. The observation that many tumors express EGF receptor (EGFR), yet only a small subset with EGFR-activating mutations respond clinically to EGFR inhibitors (EGFRIs), suggests that responsive tumors uniquely depend on EGFR signaling for their survival. The nature of this dependence is not understood. Here, we investigate dependence on EGFR signaling by comparing non-small-cell lung cancer cell lines driven by EGFR-activating mutations and genomic amplifications using a global proteomic analysis of phospho-tyrosine signaling. We identify an extensive receptor tyrosine kinase signaling network established in cells expressing mutated and activated EGFR or expressing amplified c-Met. We show that in drug sensitive cells the targeted tyrosine kinase drives other RTKs and an extensive network of downstream signaling that collapse with drug treatment. Comparison of the signaling networks in EGFR and c-Met-dependent cells identify a "core network" of approximately 50 proteins that participate in pathways mediating drug response.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-10856930, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-12098689, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-12118079, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-14617781, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-15118073, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-15118125, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-15174125, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-15284455, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-15314609, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-15329413, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-15592455, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-15657067, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-15696205, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-15731348, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-15737014, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-15815931, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-15897464, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-15951569, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-15979981, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-16282176, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-16461907, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-16630889, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-16648858, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-17097564, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-17189394, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-17332364, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-17349580, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-17463250, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-17671201, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-17872411, http://linkedlifedata.com/resource/pubmed/commentcorrection/18180459-9401208
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1091-6490
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
105
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
692-7
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:18180459-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:18180459-Cell Line, Tumor, pubmed-meshheading:18180459-Drug Resistance, Neoplasm, pubmed-meshheading:18180459-Gene Expression Regulation, Neoplastic, pubmed-meshheading:18180459-Humans, pubmed-meshheading:18180459-Lung Neoplasms, pubmed-meshheading:18180459-Models, Biological, pubmed-meshheading:18180459-Neoplasm Metastasis, pubmed-meshheading:18180459-Phosphotyrosine, pubmed-meshheading:18180459-Protein Kinase Inhibitors, pubmed-meshheading:18180459-Protein-Tyrosine Kinases, pubmed-meshheading:18180459-Proteomics, pubmed-meshheading:18180459-Proto-Oncogene Proteins c-met, pubmed-meshheading:18180459-Quinazolines, pubmed-meshheading:18180459-Receptor, Epidermal Growth Factor, pubmed-meshheading:18180459-Signal Transduction
pubmed:year
2008
pubmed:articleTitle
Signaling networks assembled by oncogenic EGFR and c-Met.
pubmed:affiliation
Cell Signaling Technology Inc., 3 Trask Lane, Danvers, MA 01923, USA.
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural